Literature DB >> 22287480

The promoting effect of adiponectin in hepatocellular carcinoma.

Ming-Jenn Chen1, Yao-Tsung Yeh, King-Teh Lee, Chia-Jung Tsai, Hao-Hsien Lee, Shen-Nien Wang.   

Abstract

BACKGROUND AND OBJECTIVES: Adipokines may explain the newly established association of obesity with hepatocellular carcinoma (HCC). This study investigated if adiponectin levels in HCC patients differed from healthy controls and their potential effect in the development of HCC.
METHODS: Radioimmunoassay was used to determine serum adiponectin levels of 65 HCC patients and 165 healthy controls. The expressions of adiponectin protein in the tumor and adjacent non-tumor parts were examined by the immunoblotting method. Cell proliferation assays were used to assess the bioeffects of adiponectin in two human liver cancer cell lines.
RESULTS: Serum adiponectin levels were significantly higher in the HCC patients than the controls. Significant correlations of serum adiponectin levels with serum triglyceride levels and insulin resistance were found in the controls, but not in the HCC patients. In contrast, serum adiponectin levels significantly correlated with serum albumin and alkaline phosphatase levels in the HCC patients, but this trend was not observed in the controls. The expression pattern of adiponectin protein between the paired tumor and adjacent non-tumor tissues significantly correlated with tumor size. In vitro, adiponectin increased cell proliferation in a dose-dependent manner.
CONCLUSIONS: Increased adiponectin expressions were found in HCC and this increase might contribute to tumor growth.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22287480     DOI: 10.1002/jso.23059

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  21 in total

1.  Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation.

Authors:  Jing Shen; Chih-Ching Yeh; Qiao Wang; Irina Gurvich; Abby B Siegel; Regina M Santella
Journal:  Anticancer Res       Date:  2016-10       Impact factor: 2.480

2.  Assessment of serum adiponectin in Egyptian patients with HCV-related cirrhosis and hepatocellular carcinoma.

Authors:  K Hamdy; R Al Swaff; H A Hussein; M Gamal
Journal:  J Endocrinol Invest       Date:  2015-09-10       Impact factor: 4.256

3.  The adiponectin gene single-nucleotide polymorphism rs1501299 is associated with hepatocellular carcinoma risk.

Authors:  X Cai; Y Gan; Y Fan; J Hu; Y Jin; F Chen; T Chen; Y Sun; J Wang; W Qin; Hong Tu
Journal:  Clin Transl Oncol       Date:  2013-06-06       Impact factor: 3.405

Review 4.  Adiponectin in inflammatory and immune-mediated diseases.

Authors:  Giamila Fantuzzi
Journal:  Cytokine       Date:  2013-07-11       Impact factor: 3.861

5.  Adiponectin in chronic hepatitis C.

Authors:  Toru Arano; Hayato Nakagawa; Hitoshi Ikeda; Kazuhiko Koike
Journal:  Clin J Gastroenterol       Date:  2013-08-14

Review 6.  Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.

Authors:  Chun-Meng Jiang; Chun-Wen Pu; Ya-Hui Hou; Zhe Chen; Mohammed Alanazy; Lionel Hebbard
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

7.  Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma.

Authors:  Rong-Rong Song; Xiao-Lin Gu
Journal:  Tumour Biol       Date:  2014-12-11

8.  Adiponectin receptor expression in gastric carcinoma: implications in tumor development and progression.

Authors:  Eun Shin; Do Joong Park; Hyung-Ho Kim; Nam Hee Won; Gheeyoung Choe; Hye Seung Lee
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-29       Impact factor: 4.553

Review 9.  Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis.

Authors:  Hayato Nakagawa
Journal:  World J Hepatol       Date:  2015-08-18

10.  Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients.

Authors:  Abby B Siegel; Abhishek Goyal; Marcela Salomao; Shuang Wang; Valerie Lee; Christine Hsu; Rosa Rodriguez; Dawn L Hershman; Robert S Brown; Alfred I Neugut; Jean Emond; Tomoaki Kato; Benjamin Samstein; David Faleck; Raffi Karagozian
Journal:  Oncology       Date:  2014-10-03       Impact factor: 2.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.